Read our latest publications & news articles NewsFuture Cannabis Strategies Europe01/23/2019Echo Pharmaceuticals will be visiting Future Cannabis Strategies Europe on the 29 th & 30 th of January 2019 in London, UK. With a pharmaceutical perspective, we will be talking about the global cannabinoid market developments. Meet us there of get in contact via info@echo-pharma.com...Cannabinoid API’s on request07/10/2018Special requests of other cannabinoids can be produced in gram (g) quantities at the required degree of purity and solution....CBD API07/10/2018We supply CBD (cannabidiol >98%) as API crystals produced under cGMP guidelines for clinical use and cosmetics....THC API07/10/2018We supply Δ9-THC (delta9-tetrahydrocannabinol >98%) as Active Pharmaceutical Ingredient (API) for clinical trials and research, produced under cGMP guidelines....Active Pharmaceutical Ingredient (API)07/10/2018Echo is specialized in the isolation of cannabinoids, produced under cGMP guidelines, with a focus on API production. This has led to an interesting variety of development programs....Arvisol™07/10/2018The world’s first pure cannabidiol (CBD) tablet which contains pure CBD in fixed dosages with high, predictable bioavailability and a long, stable, shelf life at room temperature....Namisol™07/10/2018Namisol™ is the world’s first oral tablet that contains pure, natural Δ9-THC (dronabinol) in fixed dosages with high, predictable bioavailability and a long, stable shelf life at room temperature....Reference Standards.07/10/2018With the current growing demand for cannabinoids, we offer a wide range of high quality cannabinoid reference standards at competitive prices....Namisol™ with Alitra™ DDT – Clinical Studies06/19/2018Phase I studies and presentations: First In Human Trial of an Oral Tablet with Δ9-THC Namisol™. Linda E. Klumpers et al.; Eur. J. of Neurol. 17 (Supplement 3), p 493. Poster presented at the EFNS congress 2010. THC tablet NAMISOL™: first in human PK, PD and tolerability. Linda E. Klumpers et al. Poster presented at the FIGON Dutch Medicines Days 2010. First in human trial of an oral tablet with Δ9-THC (NAMISOL™). Tim L. Beumer et al. Oral presentation at the IACM conference 2011. Novel Δ(9)-tetrahydrocannabinol formulation Namisol™ has beneficial pharmacokinetics and promising pharmacodynamic effects. Linda E. Klumpers et al. Br J Clin Pharmacol. 2011; 74 (1): 42-53. Safety and pharmacokinetics of oral delta-9-tetrahydrocannbinol in healthy older subjects: A randomized contr...Popular NewsTHC APIWe supply Δ9-THC (delta9-tetrahydrocannabinol >98%) as Active Pharmaceutical Ingredient (API) for clinical trials and research, produced under cGMP guidelines....Reference Standards.With the current growing demand for cannabinoids, we offer a wide range of high quality cannabinoid reference standards at competitive prices....
Future Cannabis Strategies Europe01/23/2019Echo Pharmaceuticals will be visiting Future Cannabis Strategies Europe on the 29 th & 30 th of January 2019 in London, UK. With a pharmaceutical perspective, we will be talking about the global cannabinoid market developments. Meet us there of get in contact via info@echo-pharma.com...
Cannabinoid API’s on request07/10/2018Special requests of other cannabinoids can be produced in gram (g) quantities at the required degree of purity and solution....
CBD API07/10/2018We supply CBD (cannabidiol >98%) as API crystals produced under cGMP guidelines for clinical use and cosmetics....
THC API07/10/2018We supply Δ9-THC (delta9-tetrahydrocannabinol >98%) as Active Pharmaceutical Ingredient (API) for clinical trials and research, produced under cGMP guidelines....
Active Pharmaceutical Ingredient (API)07/10/2018Echo is specialized in the isolation of cannabinoids, produced under cGMP guidelines, with a focus on API production. This has led to an interesting variety of development programs....
Arvisol™07/10/2018The world’s first pure cannabidiol (CBD) tablet which contains pure CBD in fixed dosages with high, predictable bioavailability and a long, stable, shelf life at room temperature....
Namisol™07/10/2018Namisol™ is the world’s first oral tablet that contains pure, natural Δ9-THC (dronabinol) in fixed dosages with high, predictable bioavailability and a long, stable shelf life at room temperature....
Reference Standards.07/10/2018With the current growing demand for cannabinoids, we offer a wide range of high quality cannabinoid reference standards at competitive prices....
Namisol™ with Alitra™ DDT – Clinical Studies06/19/2018Phase I studies and presentations: First In Human Trial of an Oral Tablet with Δ9-THC Namisol™. Linda E. Klumpers et al.; Eur. J. of Neurol. 17 (Supplement 3), p 493. Poster presented at the EFNS congress 2010. THC tablet NAMISOL™: first in human PK, PD and tolerability. Linda E. Klumpers et al. Poster presented at the FIGON Dutch Medicines Days 2010. First in human trial of an oral tablet with Δ9-THC (NAMISOL™). Tim L. Beumer et al. Oral presentation at the IACM conference 2011. Novel Δ(9)-tetrahydrocannabinol formulation Namisol™ has beneficial pharmacokinetics and promising pharmacodynamic effects. Linda E. Klumpers et al. Br J Clin Pharmacol. 2011; 74 (1): 42-53. Safety and pharmacokinetics of oral delta-9-tetrahydrocannbinol in healthy older subjects: A randomized contr...
THC APIWe supply Δ9-THC (delta9-tetrahydrocannabinol >98%) as Active Pharmaceutical Ingredient (API) for clinical trials and research, produced under cGMP guidelines....
Reference Standards.With the current growing demand for cannabinoids, we offer a wide range of high quality cannabinoid reference standards at competitive prices....
